发布求助
文献互助 智能选刊 最新文献

Leukemia & Lymphoma最新文献

筛选
英文 中文
Higher relapse and worse overall survival in recipients with CTLA-4 AA genotype of rs231775 following single-unit cord blood transplantation in adults. 在成人单单位脐带血移植后，携带CTLA-4 AA基因型rs231775的受者复发率更高，总生存期更差。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-04-01 Epub Date: 2024-12-02 DOI: 10.1080/10428194.2024.2434925
Takaaki Konuma, Megumi Hamatani-Asakura, Maki Monna-Oiwa, Seiko Kato, Masamichi Isobe, Kazuaki Yokoyama, Yasuhito Nannya, Satoshi Takahashi
{"title":"Higher relapse and worse overall survival in recipients with CTLA-4 AA genotype of rs231775 following single-unit cord blood transplantation in adults.","authors":"Takaaki Konuma, Megumi Hamatani-Asakura, Maki Monna-Oiwa, Seiko Kato, Masamichi Isobe, Kazuaki Yokoyama, Yasuhito Nannya, Satoshi Takahashi","doi":"10.1080/10428194.2024.2434925","DOIUrl":"10.1080/10428194.2024.2434925","url":null,"abstract":"<p><p>We retrospectively investigated the impact of CTLA-4 polymorphism on outcomes for adult patients who received single-unit cord blood transplantation (CBT) at our institution. CTLA-4 genotyping was performed using real-time polymerase chain reaction with the TaqMan<sup>®</sup> SNP genotyping assay for rs231775. This study included 143 recipient-donor pairs. The multivariate analysis showed that recipient rs231775 AA was associated with worse overall survival (OS) (hazard ratio [HR], 2.92; <i>p</i> = 0.008) and a higher relapse rate (HR, 4.79; <i>p</i> = 0.002), but donor rs231775 was not. The rs231775 polymorphism in recipients and donors did not affect non-relapse mortality, hematopoietic recovery, or acute and chronic graft-versus-host disease. The beneficial effects of rs231775 GG+GA recipients on OS and relapse were notable in subgroups of patients with high-risk disease status and those with myeloid diseases. The polymorphism of CTLA-4 rs231775in recipients might be associated with the clinical outcomes of single-unit CBT.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"733-743"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142770333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The current understanding of chimeric antigen receptor (CAR) T-cell therapy for older patients with relapsed or refractory large B-cell lymphoma. 目前对嵌合抗原受体 (CAR) T 细胞疗法治疗复发或难治性大 B 细胞淋巴瘤老年患者的认识。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-04-01 Epub Date: 2024-12-17 DOI: 10.1080/10428194.2024.2436606
Kunhwa Kim, Dai Chihara
{"title":"The current understanding of chimeric antigen receptor (CAR) T-cell therapy for older patients with relapsed or refractory large B-cell lymphoma.","authors":"Kunhwa Kim, Dai Chihara","doi":"10.1080/10428194.2024.2436606","DOIUrl":"10.1080/10428194.2024.2436606","url":null,"abstract":"<p><p>Chimeric antigen receptor (CAR) T-cell therapy has changed treatment landscape of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and more older patients have been treated with curative intent for R/R disease, including patients previously deemed unfit for autologous stem-cell transplant with a broader application of CAR T-cell therapy. Due to the unique CAR T-cell-related toxicity and special attention needed in treating older patients, optimal patient selection and management of CAR T-cell therapy in older patients are becoming more critical. More data are emerging in the field; multiple approaches, such as geriatric and frailty assessment and multi-disciplinary work with geriatrics, are being studied for CAR T-cell therapy application. Studies support the safe use of CAR T-cell therapy in older patients, however, application of geriatric assessment tools and maximizing multi-disciplinary approach to tailor supportive care are critical to reduce morbidity and improve outcomes in older patients.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"617-627"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142837008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial. CPX-351联合gemtuzumab ozogamicin治疗复发/难治性急性髓性白血病：加州大学血液恶性肿瘤协会的一项试验
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-04-01 Epub Date: 2024-12-17 DOI: 10.1080/10428194.2024.2438809
Caspian Oliai, Sunmin Park, Lloyd E Damon, Brian A Jonas, Deepa Jeyakumar, Matthew J Wieduwilt, Aaron C Logan, Bradley Callas, Chris A Hannigan, Daria L Gaut, Gary J Schiller
{"title":"CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial.","authors":"Caspian Oliai, Sunmin Park, Lloyd E Damon, Brian A Jonas, Deepa Jeyakumar, Matthew J Wieduwilt, Aaron C Logan, Bradley Callas, Chris A Hannigan, Daria L Gaut, Gary J Schiller","doi":"10.1080/10428194.2024.2438809","DOIUrl":"10.1080/10428194.2024.2438809","url":null,"abstract":"<p><p>In this multicenter phase Ib trial, we investigated the combination of CPX-351 and gemtuzumab ozogamicin (GO) in relapsed/refractory acute myeloid leukemia (AML). Cohort A received CPX-351 plus a single dose of GO, while cohort B received two doses of GO. Thirteen participants received investigational treatment. Dose-limiting toxicities (DLTs) occurred in one participant in each cohort, with manageable adverse events. No cases of hepatic sinusoidal obstructive syndrome occurred. Out of 12 evaluable participants, four achieved complete remission (CR), three of whom were negative for measurable residual disease. The median time to recovery of hematopoiesis for responders was 37 days. CPX-351 with GO was feasible with acceptable toxicity and marrow recovery kinetics. Further evaluation in a larger patient cohort is necessary to assess the efficacy of this regimen in relapsed/refractory AML.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"773-779"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early versus late infectious complications following chimeric antigen receptor-modified T-cell therapy. 嵌合抗原受体修饰 T 细胞疗法后的早期与晚期感染并发症。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-04-01 Epub Date: 2024-12-20 DOI: 10.1080/10428194.2024.2439513
P Bindal, C A Trottier, P Elavalakanar, L E Dodge, S Kim, E Logan, S Ma, J Liegel, J Arnason, C D Alonso
{"title":"Early versus late infectious complications following chimeric antigen receptor-modified T-cell therapy.","authors":"P Bindal, C A Trottier, P Elavalakanar, L E Dodge, S Kim, E Logan, S Ma, J Liegel, J Arnason, C D Alonso","doi":"10.1080/10428194.2024.2439513","DOIUrl":"10.1080/10428194.2024.2439513","url":null,"abstract":"<p><p>Despite increasing utilization of CAR T-cell therapy, data are lacking regarding long term follow up and risk of infectious complications after the early period following CAR T-cell infusion. In this study, we sought to compare epidemiology and risk factors for early (≤ 3 months) and late (3 months to 1 year) infections. Data were retrospectively collected at six time points: pre-CAR T, day of infusion, and at 3, 6, 9, and 12 months post CAR-T infusion for all consecutive adult patients treated at our institution. In this cohort, the cumulative incidence of any infection was 73.2% in the first year. Bridging therapy, CRS, neurotoxicity and steroid use were identified as contributing risk factors for early bacterial infections. After 3 months, community acquired respiratory infections were common. We characterize bacterial, viral and fungal pathogens based on time elapsed after CAR T-cell infusion.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"702-712"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genomic mechanisms associated with resistance to PDL1-blockade in a patient with mantle cell lymphoma. 套细胞淋巴瘤患者对pdl1阻滞剂耐药的基因组机制
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-04-01 Epub Date: 2024-12-22 DOI: 10.1080/10428194.2024.2443561
Samuel Grigg, Stephen Lade, Georgina Ryland, Sean Grimmond, Michael Dickinson, Piers Blombery
{"title":"Genomic mechanisms associated with resistance to PDL1-blockade in a patient with mantle cell lymphoma.","authors":"Samuel Grigg, Stephen Lade, Georgina Ryland, Sean Grimmond, Michael Dickinson, Piers Blombery","doi":"10.1080/10428194.2024.2443561","DOIUrl":"10.1080/10428194.2024.2443561","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"790-793"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Proteomic profiling identifies classic Hodgkin lymphoma patients at risk of bleomycin pulmonary toxicity. 蛋白质组学分析确定有博来霉素肺毒性风险的典型霍奇金淋巴瘤患者。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-04-01 Epub Date: 2024-12-03 DOI: 10.1080/10428194.2024.2434170
Maja Dam Andersen, Katharina Wolter, Marie Hairing Enemark, Kristina Lystlund Lauridsen, Stephen Jacques Hamilton-Dutoit, Jørn Starklint, Francesco d'Amore, Maja Ludvigsen, Bent Honoré, Peter Kamper
{"title":"Proteomic profiling identifies classic Hodgkin lymphoma patients at risk of bleomycin pulmonary toxicity.","authors":"Maja Dam Andersen, Katharina Wolter, Marie Hairing Enemark, Kristina Lystlund Lauridsen, Stephen Jacques Hamilton-Dutoit, Jørn Starklint, Francesco d'Amore, Maja Ludvigsen, Bent Honoré, Peter Kamper","doi":"10.1080/10428194.2024.2434170","DOIUrl":"10.1080/10428194.2024.2434170","url":null,"abstract":"<p><p>Advances in treating classic Hodgkin lymphoma (cHL) have improved cure rates, with overall survival exceeding 80%, resulting in a growing population of survivors at risk of long-term complications, particularly cardiac and pulmonary toxicity. Bleomycin, a key component of combination chemotherapy, is associated with bleomycin-induced pulmonary toxicity (BPT). Using label-free quantification nano liquid chromatography-tandem mass spectrometry, protein expression in diagnostic lymphoma samples from patients with and without BPT was compared. Results showed differential protein expression and disrupted cellular pathways, suggesting biological differences in BPT risk. Immunohistochemical analysis revealed higher expression of JAK3, BID, and MMP9, and lower expression of CD20, TPD52, and PIK3R4 in patients with BPT. High BID and low CD20 expression were associated with inferior overall survival, while high BID and low JAK3 and CD20 expression were linked to poorer progression-free survival. These findings highlight altered protein profiles in pretreatment cHL biopsies associated with BPT development.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"656-667"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142770345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
B-ALL in a 21-year-old male with X-linked agammaglobulinemia (XLA): a case report and review of B-cell malignancies in XLA. 一名患有 X 连锁丙种球蛋白血症（XLA）的 21 岁男性的 B-ALL 病例报告和 XLA B 细胞恶性肿瘤回顾。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-04-01 Epub Date: 2024-12-13 DOI: 10.1080/10428194.2024.2439529
Stephanie Franco, Joseph Fuchs, Shira Dinner, Shuo Ma
{"title":"B-ALL in a 21-year-old male with X-linked agammaglobulinemia (XLA): a case report and review of B-cell malignancies in XLA.","authors":"Stephanie Franco, Joseph Fuchs, Shira Dinner, Shuo Ma","doi":"10.1080/10428194.2024.2439529","DOIUrl":"10.1080/10428194.2024.2439529","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"801-803"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Natural killer cells: a new promising source for developing chimeric antigen receptor anti-cancer cells in hematological malignancies. 自然杀伤细胞：开发血液恶性肿瘤嵌合抗原受体抗癌细胞的新希望来源。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-04-01 Epub Date: 2024-12-10 DOI: 10.1080/10428194.2024.2438802
Shahrzad Mousavi, Mohammad Hossein Khazaee-Nasirabadi, Maryam Sadat Seyedmehdi, Ali Bazi, Roohollah Mirzaee Khalilabadi
{"title":"Natural killer cells: a new promising source for developing chimeric antigen receptor anti-cancer cells in hematological malignancies.","authors":"Shahrzad Mousavi, Mohammad Hossein Khazaee-Nasirabadi, Maryam Sadat Seyedmehdi, Ali Bazi, Roohollah Mirzaee Khalilabadi","doi":"10.1080/10428194.2024.2438802","DOIUrl":"10.1080/10428194.2024.2438802","url":null,"abstract":"<p><p>In recent times, the application of CAR-T cell treatment has significantly progressed, showing auspicious treatment outcomes in hematologic malignancies. However, along with these advances, certain limitations and challenges hurdle the widespread utilization of this technology. Recently, CAR-NK cells have gained attention in cancer treatment, as this approach has an important advantage over CART therapy (i.e. no need for HLA matching) for targeting foreign cells. This review aims to explore the benefits of CAR NK cell therapy, and generation strategies, as well as the challenges and limitations hindering the application of CAR NK cells in experimental studies and trials on hematologic malignancies.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"594-616"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic challenges of high-grade myeloid malignancies with partial plasmacytoid dendritic cell differentiation: report of two cases with literature review. 部分质体树突状细胞分化的高级别髓系恶性肿瘤的诊断难题：两例病例报告及文献综述。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-04-01 Epub Date: 2024-12-20 DOI: 10.1080/10428194.2024.2422846
Karen Amelia Nahmod, Roberto N Miranda, Francisco Vega, Beenu Thakral, Naveen Pemmaraju, Guillermo Montalban-Bravo, Sanam Loghavi, Fatima Zahra Jelloul, Wei Wang, Sa Wang, Tariq Muzzafar, Keyur Patel, Carlos E Bueso-Ramos, L Jeffrey Medeiros, Rashmi Kanagal-Shamanna
{"title":"Diagnostic challenges of high-grade myeloid malignancies with partial plasmacytoid dendritic cell differentiation: report of two cases with literature review.","authors":"Karen Amelia Nahmod, Roberto N Miranda, Francisco Vega, Beenu Thakral, Naveen Pemmaraju, Guillermo Montalban-Bravo, Sanam Loghavi, Fatima Zahra Jelloul, Wei Wang, Sa Wang, Tariq Muzzafar, Keyur Patel, Carlos E Bueso-Ramos, L Jeffrey Medeiros, Rashmi Kanagal-Shamanna","doi":"10.1080/10428194.2024.2422846","DOIUrl":"10.1080/10428194.2024.2422846","url":null,"abstract":"<p><p>The diagnosis of myeloid neoplasms with plasmacytoid dendritic cell (pDC) differentiation can be challenging due to immunophenotypic overlap requiring detailed characterization by flow cytometry and immunohistochemistry. We describe two patients with a history of myeloproliferative neoplasm (MPN) and myelodysplastic/myeloproliferative neoplasm (MDS/MPN) who presented years later with leukocytosis, lymphadenopathy, splenomegaly, and cachexia, with rapid clinical deterioration and death. Lymph node biopsy specimens revealed involvement by myeloid sarcoma with prominent pDC differentiation. Furthermore, concomitant bone marrow aspiration and biopsy showed involvement by the underlying myeloid neoplasm but no parallel expansion of pDC, as seen in the lymph node specimens, suggesting that pDC differentiation is fostered in the lymph node microenvironment. These two cases could represent the \"myeloid sarcoma\" counterpart of the recently described acute myeloid leukemia with pDC differentiation (pDC-AML). Although patients with pDC-AML have an inferior outcome when treated with conventional therapies, the recognition of a pDC component in these neoplasms potentially expands the therapeutic options.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"764-772"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular, clinical, and prognostic implications of RAS pathway alterations in adult acute myeloid leukemia. 成人急性髓性白血病RAS通路改变的分子、临床和预后意义。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-04-01 Epub Date: 2025-01-02 DOI: 10.1080/10428194.2024.2441855
Fenghong Zhang, Yizi Liu, Yiyan Zhu, Qingyuan Wang, Xiangyu Zhao, Qian Wang, Yu Chen, Suning Chen
{"title":"Molecular, clinical, and prognostic implications of RAS pathway alterations in adult acute myeloid leukemia.","authors":"Fenghong Zhang, Yizi Liu, Yiyan Zhu, Qingyuan Wang, Xiangyu Zhao, Qian Wang, Yu Chen, Suning Chen","doi":"10.1080/10428194.2024.2441855","DOIUrl":"10.1080/10428194.2024.2441855","url":null,"abstract":"<p><p>Alterations in the RAS pathway underscore the pathogenic complexity of acute myeloid leukemia (AML), yet the full spectrum, including <i>CBL</i>, <i>NF1</i>, <i>PTPN11</i>, <i>KRAS</i>, and <i>NRAS</i>, remains to be fully elucidated. In this retrospective study of 735 adult AML patients, the incidence of RAS pathway alterations was 32.4%, each with distinct clinical characteristics. Venetoclax combined with hypomethylating agents (VEN + HMA) did not significantly improve response rates compared to intensive chemotherapy (IC) group. In the IC group, <i>PTPN11</i> mutations in the N-SH2 domain showed a trend toward poorer prognosis, though not statistically significant in multivariate analysis, while <i>NRAS</i> mutations correlated with improved outcomes. In the VEN + HMA group, <i>PTPN11</i> mutations in the N-SH2 domain emerged as an independent adverse prognostic marker. <i>NRAS</i> or <i>KRAS</i> mutations showed no survival advantage compared to wild-type, aligning with their intermediate-risk classification in the 2024 ELN guidelines. These findings emphasize the need for treatment-specific risk stratification for RAS pathway mutations in AML.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"753-763"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142915388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信